Imugene Limited (ASX:IMU – Get Free Report) insider Paul Hopper sold 5,242,277 shares of the company’s stock in a transaction on Friday, April 19th. The shares were sold at an average price of A$0.07 ($0.05), for a total value of A$382,686.22 ($246,894.34).
Paul Hopper also recently made the following trade(s):
- On Wednesday, April 17th, Paul Hopper sold 4,380,952 shares of Imugene stock. The shares were sold at an average price of A$0.08 ($0.05), for a total value of A$363,619.02 ($234,592.91).
- On Thursday, February 1st, Paul Hopper 1,381,422 shares of Imugene stock.
Imugene Stock Performance
The company has a quick ratio of 15.17, a current ratio of 5.73 and a debt-to-equity ratio of 3.33.
Imugene Company Profile
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer.
See Also
- Five stocks we like better than Imugene
- Industrial Products Stocks Investing
- 3 Stocks Leading the U.S. Agriculture Comeback
- Upcoming IPO Stock Lockup Period, Explained
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Imugene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imugene and related companies with MarketBeat.com's FREE daily email newsletter.
